http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 08:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+Jun+02/26587819.html si-local-file:///var/storage/secattach/20260602/26587819.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+Jun+02/26587819.html Tue, 02 Jun 2026 08:01:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+Jun+02/26587819.html si-local-file:///var/storage/secattach/20260602/26587819.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+Jun+02/26587819.html Tue, 02 Jun 2026 08:01:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+Jun+01/26579632.html si-local-file:///var/storage/secattach/20260601/26579632.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+Jun+01/26579632.html Mon, 01 Jun 2026 08:03:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+Jun+01/26579632.html si-local-file:///var/storage/secattach/20260601/26579632.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+Jun+01/26579632.html Mon, 01 Jun 2026 08:03:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507702.html si-local-file:///var/storage/secattach/20260515/26507702.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507702.html Fri, 15 May 2026 17:07:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507702.html si-local-file:///var/storage/secattach/20260515/26507702.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507702.html Fri, 15 May 2026 17:07:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+TORONTO+DOMINION+BANK/26503449.html si-local-file:///var/storage/secattach/20260515/26503449.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+TORONTO+DOMINION+BANK/26503449.html Fri, 15 May 2026 13:46:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+TORONTO+DOMINION+BANK/26503449.html si-local-file:///var/storage/secattach/20260515/26503449.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+TORONTO+DOMINION+BANK/26503449.html Fri, 15 May 2026 13:46:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26501268.html si-local-file:///var/storage/secattach/20260515/26501268.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26501268.html Fri, 15 May 2026 10:07:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26501268.html si-local-file:///var/storage/secattach/20260515/26501268.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26501268.html Fri, 15 May 2026 10:07:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26499983.html si-local-file:///var/storage/secattach/20260515/26499983.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26499983.html Fri, 15 May 2026 08:22:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26499983.html si-local-file:///var/storage/secattach/20260515/26499983.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immatics+N.V.++++++++++++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26499983.html Fri, 15 May 2026 08:22:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+May+12/26472929.html si-local-file:///var/storage/secattach/20260512/26472929.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+May+12/26472929.html Tue, 12 May 2026 07:08:00 -0400 IMTX O.47053124 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+May+12/26472929.html si-local-file:///var/storage/secattach/20260512/26472929.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Immatics+N.V.+++++++++++++For%3A+May+12/26472929.html Tue, 12 May 2026 07:08:00 -0400 IMTX O.47053124 http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124 http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124 http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124 http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124 http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124 http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124 http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124 http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Press+Releases/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124 http://www.streetinsider.com/Globe+Newswire/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Globe+Newswire/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124 http://www.streetinsider.com/Globe+Newswire/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Globe+Newswire/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124 http://www.streetinsider.com/Globe+Newswire/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html <ul type="disc"><li style="text-align:justify;">SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027<br/><br/></li><li style="text-align:justify;">Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indications <br/><br/></li><li style="text-align:justify;">Phase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancers<br/><br/></li><li style="text-align:justify;">Phase 1b clinical data from PRAME http://www.streetinsider.com/Globe+Newswire/Immatics+Announces+First+Quarter+2026+Financial+Results+and+Business+Update/26472753.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.20939327 A.26566475 IMTX O.07320020 O.17222856 O.20026344 O.47053124